Industries > Pharma > Artificial Intelligence (AI) in Drug Discovery Market Report 2021-2031
Artificial Intelligence (AI) in Drug Discovery Market Report 2021-2031
Forecasts by Technology (Machine Learning, Other Technologies), by Application (Drug Optimisation & Repurposing, Preclinical Testing, Others), by Therapeutic Area (Oncology, Neurodegenerative Diseases, Cardiovascular Diseases, Metabolic Diseases, Infectious Diseases, Others), by End-user (Pharmaceutical & Biotechnology Companies, Contract Research Organisation, Research Center, Academic & Government Institutes) AND Regional and Leading National Market Analysis PLUS Analysis of Leading AI in Drug Discovery Companies AND COVID-19 Recovery Scenarios
PUBLISHED: 31 March 2021
PAGES: 1220
PRODUCT CODE: PHA1121
Global AI in Drug Discovery Market – our new study reveals trends, R&D progress, and predicted revenues
How will the global AI in Drug Discovery industry evolve during the forecast period from 2021-2031? If you are involved in this sector you must read this newly updated report. As the report provides details about the commercial trends, market shares, industrial activities, revenues, economic and social landscapes and other factors. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities and business prospects there. In addition, the report would also help you to enhance your strategic decision making, strengthen the analysis of competitors, allows you to formulate growth strategies, and maximise profitability of the company.
Discover how to stay ahead
Our 1220-page report provides 641 tables and 637 charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing AI in Drug Discovery Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), Porters Five Forces Analysis, Value Chain Analysis, product profiles and commercial developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.
To access the data contained in this document please email contactus@visiongain.com
Discover sales predictions for the world market and submarkets
Global AI in Drug Discovery Market: By Technology
• Machine Learning
• Other Technologies
Global AI in Drug Discovery Market: By Application
• Drug Optimisation & Repurposing
• Preclinical Testing
• Others
Global AI in Drug Discovery Market: By Therapeutic Area
• Oncology
• Neurodegenerative Diseases
• Cardiovascular Diseases
• Metabolic Diseases
• Infectious Diseases
• Others
Global AI in Drug Discovery Market: By End User
• Pharmaceutical & Biotechnology Companies
• Research Organisation
• Research Centre, Academic & Government Institutes
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
• North America
– U.S.
– Canada
• Europe
– Germany
– France
– United Kingdom
– Italy
– Spain
– Rest of Europe
• Asia Pacific
– China
– Japan
– India
– South Korea
– Rest of Asia Pacific
• Latin America
– Brazil
– Mexico
– Argentina
– Rest of Latin America
• Middle East and Africa
– South Africa
– UAE
– Rest of Middle East and Africa
Need industry data? Please contact us today.
The report also includes profiles and for some of the leading companies in the Global AI in Drug Discovery Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for AI in Drug Discovery Market will surpass $xx Million in 2021, our work calculates it grow in near future. Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Global AI in Drug Discovery Market report helps you
In summary, our 1220+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Global AI in Drug Discovery Market, with forecasts for Technology, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for Global AI in Drug Discovery Market, with forecasts for Application, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for Global AI in Drug Discovery Market, with forecasts for Therapeutic Area, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for Global AI in Drug Discovery Market, with forecasts for End User, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 20 key national markets – See forecasts for the AI in Drug Discovery market in North America, Europe, Asia-Pacific, Latin America and Middle-East & Africa. Also forecasted is the market in the US, Canada, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 18 of the major companies involved in the Global AI in Drug Discovery Market. Some of the company’s profiled in this report include IBM Corporation, Exscientia, GNS Healthcare, DeepMind, Benevolent AI, BioSymetrics, Euretos, BERG LLC, Atomwise, Inc. and others.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Global AI in Drug Discovery Market and leading companies. You will find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Artificial Intelligence (AI) in Drug Discovery Market Report 2021-2031: Forecasts by Technology (Machine Learning, Other Technologies), by Application (Drug Optimisation & Repurposing, Preclinical Testing, Others), by Therapeutic Area (Oncology, Neurodegenerative Diseases, Cardiovascular Diseases, Metabolic Diseases, Infectious Diseases, Others), by End-user (Pharmaceutical & Biotechnology Companies, Contract Research Organisation, Research Center, Academic & Government Institutes) AND Regional and Leading National Market Analysis PLUS Analysis of Leading AI in Drug Discovery Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Global Artificial Intelligence (AI) in Drug Discovery Market
1.2. Global Artificial Intelligence (AI) in Drug Discovery Market
1.3. Why You Should Read This Report?
1.4. How This Report Delivers?
1.5. Key Questions Answered by This Analytical Report?
1.6. Who is This Report For?
1.7. Methodology
1.8. Frequently Asked Questions (FAQ)
1.9. Associated Visiongain Reports
1.10. About Visiongain
2. Executive Summary
3. AI in Drug Discovery Market Dynamics
3.1. Market Dynamics: Global AI in Drug Discovery Market
3.1.1. Drivers
3.1.1.1. Reducing Cost of Drug Discovery & Development Supports the Growth of AI in Drug Discovery
3.1.1.2. Rising uptake of technology bolsters the market growth
3.1.1.3. Slow Pace for Research & Development Spending Drives the need for AI incorporation
3.1.1.4. AI helps to Expedite the Drug Discovery Process
3.1.2. Restraints
3.1.2.1. Information of Intellectual Property Leak Can Restrict the Growth
3.1.3. Opportunities
3.1.3.1. Rising Focus on Targeted Therapies
3.1.3.2. Budding Biotechnology Industry
3.2. Porter’s Five Forces Analysis: Global AI in Drug Discovery Market
3.2.1. Threat of New Entrants
3.2.2. Threat of Substitutes
3.2.3. Bargaining Power of Suppliers
3.2.4. Bargaining Power of Buyers
3.2.5. Competitive Rivalry
3.3. Value Chain Analysis: Drug Discovery Market
4. Global AI in Drug Discovery Market by Technology, 2020-2031
4.1. Leading AI in Drug Discovery Market, by Technology 2021
4.2. Global AI in Drug Discovery Market, by Technology – Coronavirus Impact Scenario VUWL Recoveries
4.3. Global Machine Learning Market
4.3.1. Global Machine Learning Market – Coronavirus Impact Scenario VUWL Recoveries
4.4. Global Other Technologies Market
4.4.1. Global Other Technologies Market – Coronavirus Impact Scenario VUWL Recoveries
5. Global AI in Drug Discovery Market by Application, 2020-2031
5.1. Leading AI in Drug Discovery Market, by Application 2021
5.2. Global AI in Drug Discovery Market, by Application – Coronavirus Impact Scenario VUWL Recoveries
5.3. Global Drug Optimisation & Repurposing Market
5.3.1. Global Drug Optimisation & Repurposing Market – Coronavirus Impact Scenario VUWL Recoveries
5.4. Global Preclinical Testing Market
5.5. Global Others Market
5.5.1. Global Others Market – Coronavirus Impact Scenario VUWL Recoveries
6. Global AI in Drug Discovery Market by Therapeutic Areas, 2020-2031
6.1. Leading AI in Drug Discovery Market, by Therapeutic Areas 2021
6.2. Global AI in Drug Discovery Market, by Therapeutic Area – COVID Impact Scenario (U, V, W, L)
6.3. Global Oncology Market
6.3.1. Global Oncology Market – Coronavirus Impact Scenario VUWL Recoveries
6.4. Global Neurodegenerative Diseases Market
6.4.1. Global Neurodegenerative Diseases Market – Coronavirus Impact Scenario VUWL Recoveries
6.5. Global Cardiovascular Diseases Market
6.5.1. Global Cardiovascular Diseases Market – Coronavirus Impact Scenario VUWL Recoveries
6.6. Global Metabolic Diseases Market
6.6.1. Global Metabolic Diseases Market – Coronavirus Impact Scenario VUWL Recoveries
6.7. Global Infectious Diseases Market
6.7.1. Global Infectious Diseases Market – Coronavirus Impact Scenario VUWL Recoveries
6.8. Global Others Market
6.8.1. Global Others Market – Coronavirus Impact Scenario VUWL Recoveries
7. Global AI in Drug Discovery Market by End User, 2020-2031
7.1. Leading AI in Drug Discovery Market, by End User 2021
7.2. Global AI in Drug Discovery Market, by End User – Coronavirus Impact Scenario VUWL Recoveries
7.3. Global Pharmaceutical & Biotechnology Companies Market
7.3.1. Global Pharmaceutical & Biotechnology Companies Market – Coronavirus Impact Scenario VUWL Recoveries
7.4. Global Contract Research Organisation Market
7.4.1. Global Contract Research Organisation Market – Coronavirus Impact Scenario VUWL Recoveries
7.5. Global Research Centre & Academic and Government Institutes Market
7.5.1. Global Research Centre & Academic and Government Institutes Market – Coronavirus Impact Scenario VUWL Recoveries
8. Global AI in Drug Discovery Market by Region, 2020-2031
8.1. Leading AI in Drug Discovery Market, by Region 2021
8.2. Global AI in Drug Discovery Market, by Region – Coronavirus Impact Scenario VUWL Recoveries
9. North America Market
9.1. North America Market – Coronavirus Impact Scenario VUWL Recoveries
9.2. U.S. Market
9.2.1. Increasing research and development activities for new drugs drives the growth of the U.S. AI in drug discovery market
9.2.2. Majority of the key players are domiciled in the region
9.2.3. U.S. Market – Coronavirus Impact Scenario VUWL Recoveries
9.3. Canada Market
9.3.1. Favorable government healthcare funding supports the growth of Canada AI in drug discovery market
9.3.2. Canada Market – Coronavirus Impact Scenario VUWL Recoveries
10. Europe Market
10.1. Europe Market – Coronavirus Impact Scenario VUWL Recoveries
10.2. U.K. Market
10.2.1. Increasing drug discovery for rare diseases propels the growth of the U.K. AI in drug discovery market
10.2.2. Rising research and development activities for developing new and innovative drugs
10.2.3. U.K. Market – Coronavirus Impact Scenario VUWL Recoveries
10.3. Germany Market
10.3.1. Increasing technological advancements helps to reduce the drug development cost thereby, supporting the growth of the market
10.3.2. Germany Market – Coronavirus Impact Scenario VUWL Recoveries
10.4. France Market
10.4.1. Rising research and development activities for developing new and innovative drugs for rare diseases
10.4.2. France Market – Coronavirus Impact Scenario VUWL Recoveries
10.5. Italy Market
10.5.1. Increasing number of companies in developing software base for early drug discovery drives the market growth
10.5.2. Growing drug manufacturing base in the country supports the market growth
10.5.3. Italy Market – Coronavirus Impact Scenario VUWL Recoveries
10.6. Spain Market
10.6.1. Rising research and development activities
10.6.2. Spain Market – Coronavirus Impact Scenario VUWL Recoveries
10.7. Rest of Europe Market
10.7.1. Rising need for new and innovative drugs at the earliest propels the market growth
10.7.2. Rest of Europe Market – Coronavirus Impact Scenario VUWL Recoveries
11. Asia Pacific Market
11.1. Asia Pacific Market – Coronavirus Impact Scenario VUWL Recoveries
11.2. China Market
11.2.1. Low cost of clinical trials supports the growth of AI in drug discovery
11.2.2. Increasing number of companies establishing their presence in the AI in drug discovery market
11.2.3. China Market – Coronavirus Impact Scenario VUWL Recoveries
11.3. India Market
11.3.1. Rising geriatric population propels the market growth
11.3.2. Rising prevalence of critical diseases
11.3.3. India Market – Coronavirus Impact Scenario VUWL Recoveries
11.4. Japan Market
11.4.1. Rising geriatric population propels the need for new and improved drugs
11.4.2. Japan Market – Coronavirus Impact Scenario VUWL Recoveries
11.5. South Korea Market
11.5.1. Favorable geographic location supports the market growth in the region
11.5.2. Increasing uptake of AI in drug discovery and development
11.5.3. South Korea Market – Coronavirus Impact Scenario VUWL Recoveries
11.6. Rest of Asia Pacific Market
11.6.1. Increasing research and development activities drive the market growth
11.6.2. Rest of Asia Pacific Market – Coronavirus Impact Scenario VUWL Recoveries
12. Latin America Market
12.1. Latin America Market – Coronavirus Impact Scenario VUWL Recoveries
12.2. Brazil Market
12.2.1. The region is identified as one of the lucrative market in Latin America
12.2.2. Brazil Market – Coronavirus Impact Scenario VUWL Recoveries
12.3. Mexico Market
12.3.1. Increasing healthcare awareness supports the market growth
12.3.2. Mexico Market – Coronavirus Impact Scenario VUWL Recoveries
12.4. Argentina Market
12.4.1. Argentina Market – Coronavirus Impact Scenario VUWL Recoveries
12.5. Rest of Latin America (LATAM) Market
12.5.1. Rest of LATAM Market – Coronavirus Impact Scenario VUWL Recoveries
13. Middle East & Africa Market
13.1. Middle East & Africa Market – Coronavirus Impact Scenario VUWL Recoveries
13.2. South Africa Market
13.2.1. Rising demand for healthcare drives the market growth
13.2.2. South Africa Market – Coronavirus Impact Scenario VUWL Recoveries
13.3. UAE Market
13.3.1. Increasing sedentary lifestyle
13.3.2. UAE Market – Coronavirus Impact Scenario VUWL Recoveries 920
13.4. Rest of MEA Market
13.4.1. Growing demand for pharmaceutical products accentuates the growth of the market
13.4.2. Rest of MEA Market – Coronavirus Impact Scenario VUWL Recoveries
14. Market Analysis
14.1. Company Share Analysis, 2020
15. Company Profile
15.1. IBM Corporation
15.1.1. Company Overview
15.1.2. Company Snapshot
15.1.3. Financial Outlook, 2015-2019
15.1.4. Product Portfolio
15.1.5. Strategic Developments, 2019-2020
15.2. Exscientia
15.2.1. Company Overview
15.2.2. Company Snapshot
15.2.3. Product Portfolio
15.2.4. Strategic Developments, 2019-2020
15.3. GNS Healthcare
15.3.1. Company Overview
15.3.2. Company Snapshot
15.3.3. Product Portfolio
15.3.4. GNS Healthcare, 2019-2020
15.4. DeepMind
15.4.1. Company Overview
15.4.2. Company Snapshot
15.4.3. Product Portfolio
15.4.4. Strategic Developments, 2018-2019
15.5. Benevolent AI
15.5.1. Company Overview
15.5.2. Company Snapshot
15.5.3. Product Portfolio
15.5.4. Strategic Developments, 2019-2020
15.6. BioSymetrics
15.6.1. Company Overview
15.6.2. Company Snapshot
15.6.3. Product Portfolio
15.6.4. Strategic Developments, 2020
15.7. Euretos
15.7.1. Company Overview
15.7.2. Company Snapshot
15.7.3. Product Portfolio
15.7.4. Strategic Developments, 2018
15.8. BERG LLC
15.8.1. Company Overview
15.8.2. Company Snapshot
15.8.3. Product Portfolio
15.8.4. Strategic Developments, 2020
15.9. Atomwise, Inc.
15.9.1. Company Overview
15.9.2. Company Snapshot
15.9.3. Product Portfolio
15.9.4. Strategic Developments, 2018-2020
15.10. Insitro
15.10.1. Company Overview
15.10.2. Company Snapshot
15.10.3. Product Portfolio
15.10.4. Strategic Developments, 2019-2020
15.11. Microsoft Corporation
15.11.1. Company Overview
15.11.2. Company Snapshot
15.11.3. Financial Outlook, 2016-2020
15.11.4. Product Portfolio
15.11.5. Strategic Developments, 2018-2020
15.12. NVIDIA Corporation
15.12.1. Company Overview
15.12.2. Company Snapshot
15.12.3. Financial Outlook, 2015-2019
15.12.4. Product Portfolio
15.12.5. Strategic Developments, 2020
15.13. Cyclica
15.13.1. Company Overview
15.13.2. Company Snapshot
15.13.3. Product Portfolio
15.13.4. Strategic Developments, 2018-2020
15.14. Deep Genomics
15.14.1. Company Overview
15.14.2. Company Snapshot
15.14.3. Product Portfolio
15.14.4. Strategic Developments, 2018-2020
15.15. Cloud Pharmaceuticals, Inc.
15.15.1. Company Overview
15.15.2. Company Snapshot
15.15.3. Product Portfolio
15.15.4. Strategic Developments, 2018
15.16. Owkin, Inc.
15.16.1. Company Overview
15.16.2. Company Snapshot
15.16.3. Product Portfolio
15.16.4. Strategic Developments, 2020
15.17. Verge Genomics
15.17.1. Company Overview
15.17.2. Company Snapshot
15.17.3. Product Portfolio
15.17.4. Strategic Developments, 2018
15.18. XtalPi, Inc.
15.18.1. Company Overview
15.18.2. Company Snapshot
15.18.3. Product Portfolio
15.18.4. Strategic Developments, 2019
16. Conclusion & Recommendations
16.1. Concluding Remarks from Visiongain
16.1.1 Leading Global AI in Drug Discovery Market, by Technology
16.1.2 Leading Global AI in Drug Discovery Market, by Application
16.1.3 Leading Global AI in Drug Discovery Market, by Therapeutic Area
16.1.4 Leading Global AI in Drug Discovery Market, by End User
16.2 Recommendations
16.3 North America dominated the global AI in Drug Discovery Market
17 Glossary
18 List of Companies & Organisations
18.2 List of Companies
18.3 List of Organisations
List of Tables
TABLE 1. GLOBAL AI IN DRUG DISCOVERY MARKET: REVENUE SNAPSHOT, 2021-2031
TABLE 2. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 3. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 4. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 5. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 6. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 7. GLOBAL MACHINE LEARNING MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 8. GLOBAL MACHINE LEARNING MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 9. GLOBAL MACHINE LEARNING MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 10. GLOBAL MACHINE LEARNING MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 11. GLOBAL MACHINE LEARNING MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 12. GLOBAL OTHER TECHNOLOGIES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 13. GLOBAL OTHER TECHNOLOGIES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 14. GLOBAL OTHER TECHNOLOGIES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 15. GLOBAL OTHER TECHNOLOGIES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 16. GLOBAL OTHER TECHNOLOGIES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 17. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 18. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 19. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 20. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 21. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 22. GLOBAL DRUG OPTIMIZATION & REPURPOSING MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 23. GLOBAL DRUG OPTIMIZATION & REPURPOSING MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 24. GLOBAL DRUG OPTIMIZATION & REPURPOSING MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 25. GLOBAL DRUG OPTIMIZATION & REPURPOSING MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 26. GLOBAL DRUG OPTIMIZATION & REPURPOSING MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 27. GLOBAL PRECLINICAL TESTING MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
BAL PRECLINICAL TESTING MARKET – CORONAVIRUS IMPACT SCENARIO VUWL RECOVERIES
TABLE 28. GLOBAL PRECLINICAL TESTING MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 29. GLOBAL PRECLINICAL TESTING MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 30. GLOBAL PRECLINICAL TESTING MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 31. GLOBAL PRECLINICAL TESTING MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 32. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 33. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 34. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 35. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 36. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 37. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 38. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 39. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 40. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 41. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 42. GLOBAL ONCOLOGY MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 43. GLOBAL ONCOLOGY MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
ARIO, THE GLOBAL ONCOLOGY SEGMENT WAS VALUED AT $60.8MN IN 2020 AND IS EXPECTED TO GROW AT A CAGR OF 23.1% FROM 2021 TO 2031 TO REACH AN ESTIMATED VALUE OF $ 491.5MN BY 2031.
TABLE 45. GLOBAL ONCOLOGY MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 46. GLOBAL ONCOLOGY MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 47. GLOBAL NEURODEGENERATIVE DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 48. GLOBAL NEURODEGENERATIVE DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 49. GLOBAL NEURODEGENERATIVE DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 50. GLOBAL NEURODEGENERATIVE DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 51. GLOBAL NEURODEGENERATIVE DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 52. GLOBAL CARDIOVASCULAR DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 53. GLOBAL CARDIOVASCULAR DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 54. GLOBAL CARDIOVASCULAR DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 55. GLOBAL CARDIOVASCULAR DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 56. GLOBAL CARDIOVASCULAR DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 57. GLOBAL METABOLIC DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 58. GLOBAL METABOLIC DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 59. GLOBAL METABOLIC DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 60. GLOBAL METABOLIC DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 61. GLOBAL METABOLIC DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 62. GLOBAL INFECTIOUS DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 63. GLOBAL INFECTIOUS DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 64. GLOBAL INFECTIOUS DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 65. GLOBAL INFECTIOUS DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 66. GLOBAL INFECTIOUS DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 67. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 68. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 69. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 70. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 71. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 72. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 73. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 74. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 75. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 76. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 77. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 78. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 79. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 80. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 81. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 82. GLOBAL CONTRACT RESEARCH ORGANIZATION MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 83. GLOBAL CONTRACT RESEARCH ORGANIZATION MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 84. GLOBAL CONTRACT RESEARCH ORGANIZATION MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 85. GLOBAL CONTRACT RESEARCH ORGANIZATION MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 86. GLOBAL CONTRACT RESEARCH ORGANIZATION MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 87. GLOBAL RESEARCH CENTRE & ACADEMIC AND GOVERNMENT INSTITUTES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 88. GLOBAL RESEARCH CENTRE & ACADEMIC AND GOVERNMENT INSTITUTES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 89. GLOBAL RESEARCH CENTRE & ACADEMIC AND GOVERNMENT INSTITUTES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 90. GLOBAL RESEARCH CENTRE & ACADEMIC AND GOVERNMENT INSTITUTES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 91. GLOBAL RESEARCH CENTRE & ACADEMIC AND GOVERNMENT INSTITUTES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 92. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY REGION MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 93. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY REGION MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 94. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY REGION MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 95. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY REGION MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 96. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY REGION MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 97. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 98. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 99. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 100. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 101. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 102. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 103. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 104. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 106. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 107. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 108. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 109. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 110. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 111. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 112. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 113. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 114. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 115. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 116. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 117. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 118. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 119. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 120. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 121. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 123. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 124. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 125. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 126. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 127. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 128. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 129. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 130. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 131. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 132. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 133. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 134. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 135. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 136. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 137. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 138. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 139. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 140. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 141. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 142. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 143. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 144. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 145. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 146. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 147. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 148. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 149. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 150. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 151. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 152. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 153. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 154. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 155. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 156. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 157. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 158. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 159. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 160. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 161. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 162. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 163. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 164. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 165. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 166. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 167. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 168. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 169. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 170. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 171. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 172. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 173. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 174. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 175. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 176. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 177. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 178. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 179. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 180. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 181. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 182. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 183. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 184. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 185. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 186. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 187. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 188. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 189. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 190. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 191. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 192. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 193. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 194. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 195. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 196. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 197. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 198. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 199. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 200. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 201. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 202. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 203. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 204. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 205. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 206. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 207. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 208. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 209. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 210. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 211. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 212. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 213. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 214. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 215. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 216. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 217. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 218. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 219. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 220. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 221. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 222. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 223. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 224. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 225. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 226. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 227. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 228. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 229. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 230. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 231. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 232. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 233. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 234. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 235. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 236. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 237. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 238. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 239. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 240. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 241. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 242. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 243. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 244. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 245. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 246. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 247. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 248. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 249. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 250. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 251. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 252. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 253. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 255. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 256. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 257. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 258. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 259. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 260. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 261. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 262. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 263. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 264. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 265. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 266. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 268. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 269. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 270. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 271. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 272. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 273. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 274. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 275. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 276. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 277. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 278. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 279. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 280. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 281. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 282. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 283. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 284. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 285. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 286. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 287. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 288. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 289. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 290. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 291. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 292. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 293. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 294. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 295. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 296. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 297. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 298. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 299. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 300. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 301. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 302. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 303. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 304. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 305. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 306. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 307. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 308. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 309. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 310. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 311. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 312. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 313. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 315. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 316. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 317. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 318. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 319. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 320. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 321. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 322. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 323. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 324. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 325. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 326. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 327. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 328. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 329. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 330. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 331. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 332. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 333. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 334. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 335. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 336. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 337. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 338. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 339. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 340. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 341. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 342. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 343. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 344. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 345. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 346. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 347. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 348. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 349. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 350. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 351. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 353. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 354. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 355. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 356. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 357. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 358. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 359. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 360. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 361. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 362. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 363. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 364. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 365. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 366. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 367. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 368. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 369. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 370. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 371. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 372. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 373. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 374. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 375. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 376. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 377. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 378. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 379. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 380. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 381. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 382. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 383. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 384. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 385. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 386. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 387. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 388. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 389. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 390. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 391. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 392. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 393. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 394. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 395. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 396. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 397. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 398. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 399. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 400. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 401. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 402. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 403. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 404. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 405. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 406. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 407. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 408. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 409. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 410. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 412. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 413. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 414. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 415. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 416. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 417. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 420. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 421. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 422. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 423. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 424. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 425. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 426. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 427. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 428. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 429. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 430. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 431. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 432. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 433. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 434. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 435. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 436. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 437. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 438. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 440. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 441. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 442. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 443. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 444. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 445. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 446. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 447. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 448. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 449. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 450. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 451. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 452. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 453. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 454. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 455. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 456. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 457. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 458. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 459. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 461. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 462. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 463. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 464. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 465. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 466. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 467. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 468. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 469. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 470. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 471. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 472. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 473. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 474. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 475. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 476. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 477. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 478. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 480. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 481. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 482. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 483. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 484. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 485. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 486. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 487. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 488. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 489. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 490. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 491. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 492. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 494. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 495. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 496. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 497. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 498. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 499. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 500. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 501. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 502. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 503. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 504. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 505. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 506. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 507. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 508. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 509. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 510. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 511. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 512. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 513. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 514. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 515. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 516. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 517. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 518. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 519. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 520. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 521. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 522. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 523. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 526. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 527. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 528. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 529. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 530. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 531. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 532. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 533. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 534. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 535. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 536. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 537. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 538. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 539. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 540. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 542. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 543. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 544. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 545. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 546. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 547. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 548. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 549. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 550. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 551. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 552. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 553. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 554. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 555. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 556. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 557. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 558. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 559. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 560. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 561. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 562. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 563. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 564. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 565. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 566. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 567. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 568. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 569. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 570. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 571. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 572. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 573. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 574. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 575. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 576. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 577. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 579. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 580. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 581. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 582. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 583. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 584. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 585. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 586. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 587. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 588. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 589. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 590. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 591. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 592. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 593. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 595. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 596. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 597. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 598. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 599. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 600. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 601. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 602. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 603. IBM CORPORATION: KEY FACTS, 2020
TABLE 605. IBM CORPORATION: STRATEGIC DEVELOPMENTS, 2019-2020
TABLE 606. EXSCIENTIA: KEY FACTS, 2020
TABLE 607. EXSCIENTIA: STRATEGIC DEVELOPMENTS, 2019-2020
TABLE 608. GNS HEALTHCARE: KEY FACTS, 2020
TABLE 609. GNS HEALTHCARE: STRATEGIC DEVELOPMENTS, 2019-2020
TABLE 610. DEEPMIND: KEY FACTS, 2020
TABLE 611. DEEPMIND: STRATEGIC DEVELOPMENTS, 2018-2019
TABLE 612. BENEVOLENT AI: KEY FACTS, 2020
TABLE 613. BENEVOLENT AI: STRATEGIC DEVELOPMENTS, 2019-2020
TABLE 614. BIOSYMETRICS: KEY FACTS, 2020
TABLE 615. BIOSYMETRICS: STRATEGIC DEVELOPMENTS, 2020
TABLE 616. EURETOS: KEY FACTS, 2020
TABLE 617. EURETOS: STRATEGIC DEVELOPMENTS, 2018
TABLE 618. BERG LLC: KEY FACTS, 2020
TABLE 619. BERG LLC: STRATEGIC DEVELOPMENTS, 2020
TABLE 621. ATOMWISE, INC.: STRATEGIC DEVELOPMENTS, 2018-2020
TABLE 624. MICROSOFT CORPORATION: KEY FACTS, 2020
TABLE 625. MICROSOFT CORPORATION: REVENUE (US$ MN), 2016-2020
TABLE 626. MICROSOFT CORPORATION: STRATEGIC DEVELOPMENTS, 2018-2020
TABLE 627. NVIDIA CORPORATION: KEY FACTS, 2020
TABLE 628. NVIDIA CORPORATION: REVENUE (US$ MN), 2015-2019
TABLE 629. NVIDIA CORPORATION: STRATEGIC DEVELOPMENTS, 2020
TABLE 630. CYCLICA: KEY FACTS,
TABLE 631. CYCLICA: STRATEGIC DEVELOPMENTS, 2018-2020
TABLE 632. DEEP GENOMICS: KEY FACTS, 2020
TABLE 633. DEEP GENOMICS: STRATEGIC DEVELOPMENTS, 2018-2020
TABLE 634. CLOUD PHARMACEUTICALS, INC.: KEY FACTS, 2020
TABLE 636. OWKIN, INC.: KEY FACTS, 2020
TABLE 637. OWKIN, INC.: STRATEGIC DEVELOPMENTS, 2020
TABLE 638. VERGE GENOMICS: KEY FACTS, 2020
TABLE 639. VERGE GENOMICS: STRATEGIC DEVELOPMENTS, 2018
TABLE 640. XTALPI, INC.: KEY FACTS, 2020
TABLE 641. XTALPI, INC.: STRATEGIC DEVELOPMENTS, 2019
List of Figures
FIGURE 1. GLOBAL AI IN DRUG DISCOVERY MARKET SEGMENTATION
FIGURE 2. MARKET DYNAMICS: GLOBAL AI IN DRUG DISCOVERY MARKET, 2021
FIGURE 3. PORTER’S FIVE FORCES ANALYSIS: GLOBAL AI IN DRUG DISCOVERY MARKET, 2021
FIGURE 4. VALUE CHAIN ANALYSIS: AI IN DRUG DISCOVERY MARKET 101
FIGURE 5. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 6. GLOBAL AI IN DRUG DISCOVERY MARKET BY TECHNOLOGY MARKET SHARE (%), 2021, 2026, AND 2031
FIGURE 7. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 8. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 9. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 10. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 11. GLOBAL MACHINE LEARNING MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 12. GLOBAL MACHINE LEARNING MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 13. GLOBAL MACHINE LEARNING MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 14. GLOBAL MACHINE LEARNING MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 15. GLOBAL MACHINE LEARNING MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 16. GLOBAL OTHER TECHNOLOGIES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 17. GLOBAL OTHER TECHNOLOGIES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 18. GLOBAL OTHER TECHNOLOGIES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 19. GLOBAL OTHER TECHNOLOGIES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 20. GLOBAL OTHER TECHNOLOGIES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 21. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 22. GLOBAL AI IN DRUG DISCOVERY MARKET BY APPLICATION MARKET SHARE (%), 2021, 2026, AND 2031
FIGURE 23. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 24. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 25. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 26. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 27. GLOBAL DRUG OPTIMIZATION & REPURPOSING MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 28. GLOBAL DRUG OPTIMIZATION & REPURPOSING MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 29. GLOBAL DRUG OPTIMIZATION & REPURPOSING MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 30. GLOBAL DRUG OPTIMIZATION & REPURPOSING MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 31. GLOBAL DRUG OPTIMIZATION & REPURPOSING MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 32. GLOBAL PRECLINICAL TESTING MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 33. GLOBAL PRECLINICAL TESTING MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 34. GLOBAL PRECLINICAL TESTING MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 35. GLOBAL PRECLINICAL TESTING MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 36. GLOBAL PRECLINICAL TESTING MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 37. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 38. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 39. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 40. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 41. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 44. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 45. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 46. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 47. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 48. GLOBAL ONCOLOGY MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 49. GLOBAL ONCOLOGY MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 50. GLOBAL ONCOLOGY MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 51. GLOBAL ONCOLOGY MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 52. GLOBAL ONCOLOGY MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 53. GLOBAL NEURODEGENERATIVE DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 54. GLOBAL NEURODEGENERATIVE DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 55. GLOBAL NEURODEGENERATIVE DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 56. GLOBAL NEURODEGENERATIVE DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 57. GLOBAL NEURODEGENERATIVE DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 58. GLOBAL CARDIOVASCULAR DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 59. GLOBAL CARDIOVASCULAR DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 60. GLOBAL CARDIOVASCULAR DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 61. GLOBAL CARDIOVASCULAR DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 63. GLOBAL METABOLIC DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 64. GLOBAL METABOLIC DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 65. GLOBAL METABOLIC DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 66. GLOBAL METABOLIC DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 67. GLOBAL METABOLIC DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 68. GLOBAL INFECTIOUS DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 69. GLOBAL INFECTIOUS DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 70. GLOBAL INFECTIOUS DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 71. GLOBAL INFECTIOUS DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 72. GLOBAL INFECTIOUS DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 73. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 74. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 75. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 76. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 77. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 78. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), 2020-2031
FIGURE 79. GLOBAL AI IN DRUG DISCOVERY MARKET BY END USER MARKET SHARE (%), 2021, 2026, AND 2031
FIGURE 80. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 81. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 82. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 83. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 84. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 86. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 87. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 88. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 89. GLOBAL CONTRACT RESEARCH ORGANIZATION MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 90. GLOBAL CONTRACT RESEARCH ORGANIZATION MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 91. GLOBAL CONTRACT RESEARCH ORGANIZATION MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 92. GLOBAL CONTRACT RESEARCH ORGANIZATION MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 93. GLOBAL CONTRACT RESEARCH ORGANIZATION MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 94. GLOBAL RESEARCH CENTRE & ACADEMIC AND GOVERNMENT INSTITUTES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 95. GLOBAL RESEARCH CENTRE & ACADEMIC AND GOVERNMENT INSTITUTES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 96. GLOBAL RESEARCH CENTRE & ACADEMIC AND GOVERNMENT INSTITUTES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 97. GLOBAL RESEARCH CENTRE & ACADEMIC AND GOVERNMENT INSTITUTES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 98. GLOBAL RESEARCH CENTRE & ACADEMIC AND GOVERNMENT INSTITUTES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 99. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY REGION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 100. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY REGION MARKET FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 101. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY REGION MARKET FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 102. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY REGION MARKET FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 103. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY REGION MARKET FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 104. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 105. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 106. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 107. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 108. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 109. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 110. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 111. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 112. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 113. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 114. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 115. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 116. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 117. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 118. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 119. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 120. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 121. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 122. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 123. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 125. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 126. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 127. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 128. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 129. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 130. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 131. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 132. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 133. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 134. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 135. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 136. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 137. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 138. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 139. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 140. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 141. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 142. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 143. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 144. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 145. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 146. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 147. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 148. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 149. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 150. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 151. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 152. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 153. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 154. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 155. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 156. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 157. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 158. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 159. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 160. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 161. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 162. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 163. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 164. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 165. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 166. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 167. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 168. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 169. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 170. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 171. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 172. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 173. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 174. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 175. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 176. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 177. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 178. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 179. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 180. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 181. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 182. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 183. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 184. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 185. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 186. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 187. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 188. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 189. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 190. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 191. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 192. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 193. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 194. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 195. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 196. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 197. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 198. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 199. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 200. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 201. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 202. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 203. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 204. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 205. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 206. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 207. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 208. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 209. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 210. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 211. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 212. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 213. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 214. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 215. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 216. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 217. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 218. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 219. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 220. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 221. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 222. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 223. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 224. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 225. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 226. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 227. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 228. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 229. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 230. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 231. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 232. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 233. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 234. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 235. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 237. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 238. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 239. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 240. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 241. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 242. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 243. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 244. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 245. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 246. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 247. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 248. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 249. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 250. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 251. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 252. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 253. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 254. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 255. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 256. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 257. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 258. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 259. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 260. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 261. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 263. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 264. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 265. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 266. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 267. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 268. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 269. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 270. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 271. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 272. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 273. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 274. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 275. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 276. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 277. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 278. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 279. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 280. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 281. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 282. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 283. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 284. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 285. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 286. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 287. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 288. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 289. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 290. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 291. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 292. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 293. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 294. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 295. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 296. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 297. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 298. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 299. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 300. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 301. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 302. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 303. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 304. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 305. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 306. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 307. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 308. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 309. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 310. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 311. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 312. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 313. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 314. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 315. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 316. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 317. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 318. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 319. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 320. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 321. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 322. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 323. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 324. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 325. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 326. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 327. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 328. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 329. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 330. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 331. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 332. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 333. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 334. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 335. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 336. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 337. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 338. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 339. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 340. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 341. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 342. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 343. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 344. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 345. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 346. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 347. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 348. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 349. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 350. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 351. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 352. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 353. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 354. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 355. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 356. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 357. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 358. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 359. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 360. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 361. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 362. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 363. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 364. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 365. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 366. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 367. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 368. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 369. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 370. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 371. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 372. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 373. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 374. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 375. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 376. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 377. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 378. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 379. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 380. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 381. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 382. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 383. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 384. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 385. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 386. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 387. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 388. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 389. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 390. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 391. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 392. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 393. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 394. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 395. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 396. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 397. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 398. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 399. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 400. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 401. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 402. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 403. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 404. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 405. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 406. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 407. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 408. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 409. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 410. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 411. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 412. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 413. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 414. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 415. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 416. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 417. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 418. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 419. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 420. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 421. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 422. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 423. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 424. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 425. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 426. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 427. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 428. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 429. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 430. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 431. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 432. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 433. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 434. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 435. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 436. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 437. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 438. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 439. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 440. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 441. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 442. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 443. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 444. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 445. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 446. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 447. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 448. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 449. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 450. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 451. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 452. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 453. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 454. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 455. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 456. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 457. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 458. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 459. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 460. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 461. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 462. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 463. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 464. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 465. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 466. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 467. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 468. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 469. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 470. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 471. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 472. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 473. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 474. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 475. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 476. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 477. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 478. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 479. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 480. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 481. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 482. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 483. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 484. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 485. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 486. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 487. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 488. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 489. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 490. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 491. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 492. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 493. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 494. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 495. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 496. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 497. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 498. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 499. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 500. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 501. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 502. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 503. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 504. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 505. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 506. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 507. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 508. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 509. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 510. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 511. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 512. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 513. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 514. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 515. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 516. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 517. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 518. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 519. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 520. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 521. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 522. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 524. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 525. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 526. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 527. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 528. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 529. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 530. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 531. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 532. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 533. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 534. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 535. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 536. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 537. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 538. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 539. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 540. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 541. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 542. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 543. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 544. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 545. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 546. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 547. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 548. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 549. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 550. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 551. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 552. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 553. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 554. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 555. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 556. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 557. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 558. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 559. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 560. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 561. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 562. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 563. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 564. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 565. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 566. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 567. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 568. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 569. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 571. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 572. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 573. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 574. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 575. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 576. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 577. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 578. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 579. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 580. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 581. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 582. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 583. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 584. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 585. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 586. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 587. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 588. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 589. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 590. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AND AGR (%)2020-2031
FIGURE 591. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 592. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 593. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 594. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 595. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 597. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 598. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 599. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 600. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 601. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 602. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 603. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 604. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 605. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 606. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 607. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 608. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 609. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 610. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 611. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 612. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 613. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 614. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 615. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 616. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 617. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 618. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 619. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 620. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 621. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 622. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 623. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 624. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 625. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 626. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 627. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 628. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 629. GLOBAL MARKET SHARE ANALYSIS (VALUE %), 2020
FIGURE 630. IBM CORPORATION: HISTORICAL REVENUE (US$ MN), 2015-2019
FIGURE 631. MICROSOFT CORPORATION: HISTORICAL REVENUE (US$ MN), 2016-2020
FIGURE 632. NVIDIA CORPORATION: HISTORICAL REVENUE (US$ MN), 2015-2019
FIGURE 634. GLOBAL AI IN DRUG DISCOVERY MARKET SHARE (%), BY APPLICATION, 2021, 2026 AND 2031
FIGURE 635. GLOBAL AI IN DRUG DISCOVERY MARKET SHARE (%), BY THERAPEUTIC AREA, 2021, 2026 AND 2031
FIGURE 636. GLOBAL AI IN DRUG DISCOVERY MARKET SHARE (%), BY END USER, 2021, 2026 AND 2031
FIGURE 637. GLOBAL AI IN DRUG DISCOVERY MARKET SHARE (%), BY REGION, 2021, 2026 AND 2031
1.1. Global Artificial Intelligence (AI) in Drug Discovery Market
1.2. Global Artificial Intelligence (AI) in Drug Discovery Market
1.3. Why You Should Read This Report?
1.4. How This Report Delivers?
1.5. Key Questions Answered by This Analytical Report?
1.6. Who is This Report For?
1.7. Methodology
1.8. Frequently Asked Questions (FAQ)
1.9. Associated Visiongain Reports
1.10. About Visiongain
2. Executive Summary
3. AI in Drug Discovery Market Dynamics
3.1. Market Dynamics: Global AI in Drug Discovery Market
3.1.1. Drivers
3.1.1.1. Reducing Cost of Drug Discovery & Development Supports the Growth of AI in Drug Discovery
3.1.1.2. Rising uptake of technology bolsters the market growth
3.1.1.3. Slow Pace for Research & Development Spending Drives the need for AI incorporation
3.1.1.4. AI helps to Expedite the Drug Discovery Process
3.1.2. Restraints
3.1.2.1. Information of Intellectual Property Leak Can Restrict the Growth
3.1.3. Opportunities
3.1.3.1. Rising Focus on Targeted Therapies
3.1.3.2. Budding Biotechnology Industry
3.2. Porter’s Five Forces Analysis: Global AI in Drug Discovery Market
3.2.1. Threat of New Entrants
3.2.2. Threat of Substitutes
3.2.3. Bargaining Power of Suppliers
3.2.4. Bargaining Power of Buyers
3.2.5. Competitive Rivalry
3.3. Value Chain Analysis: Drug Discovery Market
4. Global AI in Drug Discovery Market by Technology, 2020-2031
4.1. Leading AI in Drug Discovery Market, by Technology 2021
4.2. Global AI in Drug Discovery Market, by Technology – Coronavirus Impact Scenario VUWL Recoveries
4.3. Global Machine Learning Market
4.3.1. Global Machine Learning Market – Coronavirus Impact Scenario VUWL Recoveries
4.4. Global Other Technologies Market
4.4.1. Global Other Technologies Market – Coronavirus Impact Scenario VUWL Recoveries
5. Global AI in Drug Discovery Market by Application, 2020-2031
5.1. Leading AI in Drug Discovery Market, by Application 2021
5.2. Global AI in Drug Discovery Market, by Application – Coronavirus Impact Scenario VUWL Recoveries
5.3. Global Drug Optimisation & Repurposing Market
5.3.1. Global Drug Optimisation & Repurposing Market – Coronavirus Impact Scenario VUWL Recoveries
5.4. Global Preclinical Testing Market
5.5. Global Others Market
5.5.1. Global Others Market – Coronavirus Impact Scenario VUWL Recoveries
6. Global AI in Drug Discovery Market by Therapeutic Areas, 2020-2031
6.1. Leading AI in Drug Discovery Market, by Therapeutic Areas 2021
6.2. Global AI in Drug Discovery Market, by Therapeutic Area – COVID Impact Scenario (U, V, W, L)
6.3. Global Oncology Market
6.3.1. Global Oncology Market – Coronavirus Impact Scenario VUWL Recoveries
6.4. Global Neurodegenerative Diseases Market
6.4.1. Global Neurodegenerative Diseases Market – Coronavirus Impact Scenario VUWL Recoveries
6.5. Global Cardiovascular Diseases Market
6.5.1. Global Cardiovascular Diseases Market – Coronavirus Impact Scenario VUWL Recoveries
6.6. Global Metabolic Diseases Market
6.6.1. Global Metabolic Diseases Market – Coronavirus Impact Scenario VUWL Recoveries
6.7. Global Infectious Diseases Market
6.7.1. Global Infectious Diseases Market – Coronavirus Impact Scenario VUWL Recoveries
6.8. Global Others Market
6.8.1. Global Others Market – Coronavirus Impact Scenario VUWL Recoveries
7. Global AI in Drug Discovery Market by End User, 2020-2031
7.1. Leading AI in Drug Discovery Market, by End User 2021
7.2. Global AI in Drug Discovery Market, by End User – Coronavirus Impact Scenario VUWL Recoveries
7.3. Global Pharmaceutical & Biotechnology Companies Market
7.3.1. Global Pharmaceutical & Biotechnology Companies Market – Coronavirus Impact Scenario VUWL Recoveries
7.4. Global Contract Research Organisation Market
7.4.1. Global Contract Research Organisation Market – Coronavirus Impact Scenario VUWL Recoveries
7.5. Global Research Centre & Academic and Government Institutes Market
7.5.1. Global Research Centre & Academic and Government Institutes Market – Coronavirus Impact Scenario VUWL Recoveries
8. Global AI in Drug Discovery Market by Region, 2020-2031
8.1. Leading AI in Drug Discovery Market, by Region 2021
8.2. Global AI in Drug Discovery Market, by Region – Coronavirus Impact Scenario VUWL Recoveries
9. North America Market
9.1. North America Market – Coronavirus Impact Scenario VUWL Recoveries
9.2. U.S. Market
9.2.1. Increasing research and development activities for new drugs drives the growth of the U.S. AI in drug discovery market
9.2.2. Majority of the key players are domiciled in the region
9.2.3. U.S. Market – Coronavirus Impact Scenario VUWL Recoveries
9.3. Canada Market
9.3.1. Favorable government healthcare funding supports the growth of Canada AI in drug discovery market
9.3.2. Canada Market – Coronavirus Impact Scenario VUWL Recoveries
10. Europe Market
10.1. Europe Market – Coronavirus Impact Scenario VUWL Recoveries
10.2. U.K. Market
10.2.1. Increasing drug discovery for rare diseases propels the growth of the U.K. AI in drug discovery market
10.2.2. Rising research and development activities for developing new and innovative drugs
10.2.3. U.K. Market – Coronavirus Impact Scenario VUWL Recoveries
10.3. Germany Market
10.3.1. Increasing technological advancements helps to reduce the drug development cost thereby, supporting the growth of the market
10.3.2. Germany Market – Coronavirus Impact Scenario VUWL Recoveries
10.4. France Market
10.4.1. Rising research and development activities for developing new and innovative drugs for rare diseases
10.4.2. France Market – Coronavirus Impact Scenario VUWL Recoveries
10.5. Italy Market
10.5.1. Increasing number of companies in developing software base for early drug discovery drives the market growth
10.5.2. Growing drug manufacturing base in the country supports the market growth
10.5.3. Italy Market – Coronavirus Impact Scenario VUWL Recoveries
10.6. Spain Market
10.6.1. Rising research and development activities
10.6.2. Spain Market – Coronavirus Impact Scenario VUWL Recoveries
10.7. Rest of Europe Market
10.7.1. Rising need for new and innovative drugs at the earliest propels the market growth
10.7.2. Rest of Europe Market – Coronavirus Impact Scenario VUWL Recoveries
11. Asia Pacific Market
11.1. Asia Pacific Market – Coronavirus Impact Scenario VUWL Recoveries
11.2. China Market
11.2.1. Low cost of clinical trials supports the growth of AI in drug discovery
11.2.2. Increasing number of companies establishing their presence in the AI in drug discovery market
11.2.3. China Market – Coronavirus Impact Scenario VUWL Recoveries
11.3. India Market
11.3.1. Rising geriatric population propels the market growth
11.3.2. Rising prevalence of critical diseases
11.3.3. India Market – Coronavirus Impact Scenario VUWL Recoveries
11.4. Japan Market
11.4.1. Rising geriatric population propels the need for new and improved drugs
11.4.2. Japan Market – Coronavirus Impact Scenario VUWL Recoveries
11.5. South Korea Market
11.5.1. Favorable geographic location supports the market growth in the region
11.5.2. Increasing uptake of AI in drug discovery and development
11.5.3. South Korea Market – Coronavirus Impact Scenario VUWL Recoveries
11.6. Rest of Asia Pacific Market
11.6.1. Increasing research and development activities drive the market growth
11.6.2. Rest of Asia Pacific Market – Coronavirus Impact Scenario VUWL Recoveries
12. Latin America Market
12.1. Latin America Market – Coronavirus Impact Scenario VUWL Recoveries
12.2. Brazil Market
12.2.1. The region is identified as one of the lucrative market in Latin America
12.2.2. Brazil Market – Coronavirus Impact Scenario VUWL Recoveries
12.3. Mexico Market
12.3.1. Increasing healthcare awareness supports the market growth
12.3.2. Mexico Market – Coronavirus Impact Scenario VUWL Recoveries
12.4. Argentina Market
12.4.1. Argentina Market – Coronavirus Impact Scenario VUWL Recoveries
12.5. Rest of Latin America (LATAM) Market
12.5.1. Rest of LATAM Market – Coronavirus Impact Scenario VUWL Recoveries
13. Middle East & Africa Market
13.1. Middle East & Africa Market – Coronavirus Impact Scenario VUWL Recoveries
13.2. South Africa Market
13.2.1. Rising demand for healthcare drives the market growth
13.2.2. South Africa Market – Coronavirus Impact Scenario VUWL Recoveries
13.3. UAE Market
13.3.1. Increasing sedentary lifestyle
13.3.2. UAE Market – Coronavirus Impact Scenario VUWL Recoveries 920
13.4. Rest of MEA Market
13.4.1. Growing demand for pharmaceutical products accentuates the growth of the market
13.4.2. Rest of MEA Market – Coronavirus Impact Scenario VUWL Recoveries
14. Market Analysis
14.1. Company Share Analysis, 2020
15. Company Profile
15.1. IBM Corporation
15.1.1. Company Overview
15.1.2. Company Snapshot
15.1.3. Financial Outlook, 2015-2019
15.1.4. Product Portfolio
15.1.5. Strategic Developments, 2019-2020
15.2. Exscientia
15.2.1. Company Overview
15.2.2. Company Snapshot
15.2.3. Product Portfolio
15.2.4. Strategic Developments, 2019-2020
15.3. GNS Healthcare
15.3.1. Company Overview
15.3.2. Company Snapshot
15.3.3. Product Portfolio
15.3.4. GNS Healthcare, 2019-2020
15.4. DeepMind
15.4.1. Company Overview
15.4.2. Company Snapshot
15.4.3. Product Portfolio
15.4.4. Strategic Developments, 2018-2019
15.5. Benevolent AI
15.5.1. Company Overview
15.5.2. Company Snapshot
15.5.3. Product Portfolio
15.5.4. Strategic Developments, 2019-2020
15.6. BioSymetrics
15.6.1. Company Overview
15.6.2. Company Snapshot
15.6.3. Product Portfolio
15.6.4. Strategic Developments, 2020
15.7. Euretos
15.7.1. Company Overview
15.7.2. Company Snapshot
15.7.3. Product Portfolio
15.7.4. Strategic Developments, 2018
15.8. BERG LLC
15.8.1. Company Overview
15.8.2. Company Snapshot
15.8.3. Product Portfolio
15.8.4. Strategic Developments, 2020
15.9. Atomwise, Inc.
15.9.1. Company Overview
15.9.2. Company Snapshot
15.9.3. Product Portfolio
15.9.4. Strategic Developments, 2018-2020
15.10. Insitro
15.10.1. Company Overview
15.10.2. Company Snapshot
15.10.3. Product Portfolio
15.10.4. Strategic Developments, 2019-2020
15.11. Microsoft Corporation
15.11.1. Company Overview
15.11.2. Company Snapshot
15.11.3. Financial Outlook, 2016-2020
15.11.4. Product Portfolio
15.11.5. Strategic Developments, 2018-2020
15.12. NVIDIA Corporation
15.12.1. Company Overview
15.12.2. Company Snapshot
15.12.3. Financial Outlook, 2015-2019
15.12.4. Product Portfolio
15.12.5. Strategic Developments, 2020
15.13. Cyclica
15.13.1. Company Overview
15.13.2. Company Snapshot
15.13.3. Product Portfolio
15.13.4. Strategic Developments, 2018-2020
15.14. Deep Genomics
15.14.1. Company Overview
15.14.2. Company Snapshot
15.14.3. Product Portfolio
15.14.4. Strategic Developments, 2018-2020
15.15. Cloud Pharmaceuticals, Inc.
15.15.1. Company Overview
15.15.2. Company Snapshot
15.15.3. Product Portfolio
15.15.4. Strategic Developments, 2018
15.16. Owkin, Inc.
15.16.1. Company Overview
15.16.2. Company Snapshot
15.16.3. Product Portfolio
15.16.4. Strategic Developments, 2020
15.17. Verge Genomics
15.17.1. Company Overview
15.17.2. Company Snapshot
15.17.3. Product Portfolio
15.17.4. Strategic Developments, 2018
15.18. XtalPi, Inc.
15.18.1. Company Overview
15.18.2. Company Snapshot
15.18.3. Product Portfolio
15.18.4. Strategic Developments, 2019
16. Conclusion & Recommendations
16.1. Concluding Remarks from Visiongain
16.1.1 Leading Global AI in Drug Discovery Market, by Technology
16.1.2 Leading Global AI in Drug Discovery Market, by Application
16.1.3 Leading Global AI in Drug Discovery Market, by Therapeutic Area
16.1.4 Leading Global AI in Drug Discovery Market, by End User
16.2 Recommendations
16.3 North America dominated the global AI in Drug Discovery Market
17 Glossary
18 List of Companies & Organisations
18.2 List of Companies
18.3 List of Organisations
List of Tables
TABLE 1. GLOBAL AI IN DRUG DISCOVERY MARKET: REVENUE SNAPSHOT, 2021-2031
TABLE 2. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 3. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 4. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 5. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 6. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 7. GLOBAL MACHINE LEARNING MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 8. GLOBAL MACHINE LEARNING MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 9. GLOBAL MACHINE LEARNING MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 10. GLOBAL MACHINE LEARNING MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 11. GLOBAL MACHINE LEARNING MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 12. GLOBAL OTHER TECHNOLOGIES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 13. GLOBAL OTHER TECHNOLOGIES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 14. GLOBAL OTHER TECHNOLOGIES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 15. GLOBAL OTHER TECHNOLOGIES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 16. GLOBAL OTHER TECHNOLOGIES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 17. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 18. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 19. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 20. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 21. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 22. GLOBAL DRUG OPTIMIZATION & REPURPOSING MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 23. GLOBAL DRUG OPTIMIZATION & REPURPOSING MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 24. GLOBAL DRUG OPTIMIZATION & REPURPOSING MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 25. GLOBAL DRUG OPTIMIZATION & REPURPOSING MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 26. GLOBAL DRUG OPTIMIZATION & REPURPOSING MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 27. GLOBAL PRECLINICAL TESTING MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
BAL PRECLINICAL TESTING MARKET – CORONAVIRUS IMPACT SCENARIO VUWL RECOVERIES
TABLE 28. GLOBAL PRECLINICAL TESTING MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 29. GLOBAL PRECLINICAL TESTING MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 30. GLOBAL PRECLINICAL TESTING MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 31. GLOBAL PRECLINICAL TESTING MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 32. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 33. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 34. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 35. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 36. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 37. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 38. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 39. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 40. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 41. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 42. GLOBAL ONCOLOGY MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 43. GLOBAL ONCOLOGY MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
ARIO, THE GLOBAL ONCOLOGY SEGMENT WAS VALUED AT $60.8MN IN 2020 AND IS EXPECTED TO GROW AT A CAGR OF 23.1% FROM 2021 TO 2031 TO REACH AN ESTIMATED VALUE OF $ 491.5MN BY 2031.
TABLE 45. GLOBAL ONCOLOGY MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 46. GLOBAL ONCOLOGY MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 47. GLOBAL NEURODEGENERATIVE DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 48. GLOBAL NEURODEGENERATIVE DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 49. GLOBAL NEURODEGENERATIVE DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 50. GLOBAL NEURODEGENERATIVE DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 51. GLOBAL NEURODEGENERATIVE DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 52. GLOBAL CARDIOVASCULAR DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 53. GLOBAL CARDIOVASCULAR DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 54. GLOBAL CARDIOVASCULAR DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 55. GLOBAL CARDIOVASCULAR DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 56. GLOBAL CARDIOVASCULAR DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 57. GLOBAL METABOLIC DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 58. GLOBAL METABOLIC DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 59. GLOBAL METABOLIC DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 60. GLOBAL METABOLIC DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 61. GLOBAL METABOLIC DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 62. GLOBAL INFECTIOUS DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 63. GLOBAL INFECTIOUS DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 64. GLOBAL INFECTIOUS DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 65. GLOBAL INFECTIOUS DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 66. GLOBAL INFECTIOUS DISEASES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 67. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 68. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 69. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 70. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 71. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 72. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 73. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 74. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 75. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 76. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 77. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 78. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 79. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 80. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 81. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 82. GLOBAL CONTRACT RESEARCH ORGANIZATION MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 83. GLOBAL CONTRACT RESEARCH ORGANIZATION MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 84. GLOBAL CONTRACT RESEARCH ORGANIZATION MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 85. GLOBAL CONTRACT RESEARCH ORGANIZATION MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 86. GLOBAL CONTRACT RESEARCH ORGANIZATION MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 87. GLOBAL RESEARCH CENTRE & ACADEMIC AND GOVERNMENT INSTITUTES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 88. GLOBAL RESEARCH CENTRE & ACADEMIC AND GOVERNMENT INSTITUTES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 89. GLOBAL RESEARCH CENTRE & ACADEMIC AND GOVERNMENT INSTITUTES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 90. GLOBAL RESEARCH CENTRE & ACADEMIC AND GOVERNMENT INSTITUTES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 91. GLOBAL RESEARCH CENTRE & ACADEMIC AND GOVERNMENT INSTITUTES MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 92. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY REGION MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 93. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY REGION MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 94. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY REGION MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 95. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY REGION MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 96. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY REGION MARKET FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 97. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 98. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 99. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 100. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 101. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 102. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 103. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 104. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 106. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 107. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 108. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 109. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 110. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 111. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 112. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 113. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 114. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 115. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 116. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 117. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 118. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 119. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 120. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 121. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 123. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 124. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 125. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 126. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 127. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 128. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 129. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 130. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 131. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 132. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 133. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 134. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 135. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 136. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 137. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 138. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 139. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 140. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 141. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 142. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 143. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 144. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 145. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 146. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 147. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 148. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 149. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 150. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 151. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 152. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 153. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 154. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 155. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 156. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 157. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 158. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 159. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 160. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 161. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 162. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 163. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 164. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 165. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 166. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 167. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 168. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 169. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 170. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 171. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 172. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 173. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 174. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 175. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 176. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 177. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 178. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 179. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 180. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 181. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 182. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 183. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 184. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 185. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 186. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 187. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 188. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 189. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 190. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 191. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 192. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 193. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 194. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 195. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 196. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 197. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 198. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 199. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 200. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 201. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 202. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 203. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 204. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 205. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 206. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 207. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 208. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 209. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 210. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 211. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 212. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 213. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 214. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 215. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 216. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 217. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 218. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 219. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 220. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 221. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 222. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 223. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 224. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 225. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 226. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 227. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 228. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 229. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 230. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 231. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 232. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 233. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 234. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 235. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 236. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 237. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 238. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 239. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 240. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 241. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 242. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 243. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 244. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 245. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 246. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 247. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 248. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 249. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 250. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 251. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 252. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 253. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 255. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 256. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 257. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 258. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 259. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 260. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 261. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 262. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 263. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 264. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 265. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 266. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 268. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 269. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 270. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 271. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 272. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 273. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 274. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 275. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 276. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 277. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 278. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 279. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 280. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 281. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 282. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 283. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 284. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 285. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 286. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 287. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 288. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 289. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 290. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 291. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 292. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 293. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 294. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 295. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 296. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 297. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 298. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 299. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 300. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 301. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 302. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 303. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 304. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 305. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 306. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 307. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 308. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 309. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 310. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 311. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 312. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 313. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 315. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 316. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 317. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 318. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 319. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 320. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 321. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 322. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 323. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 324. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 325. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 326. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 327. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 328. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 329. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 330. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 331. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 332. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 333. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 334. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 335. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 336. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 337. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 338. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 339. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 340. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 341. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 342. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 343. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 344. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 345. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 346. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 347. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 348. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 349. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 350. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 351. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 353. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 354. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 355. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 356. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 357. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 358. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 359. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 360. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 361. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 362. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 363. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 364. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 365. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 366. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 367. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 368. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 369. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 370. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 371. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 372. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 373. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 374. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 375. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 376. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 377. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 378. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 379. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 380. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 381. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 382. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 383. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 384. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 385. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 386. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 387. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 388. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 389. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 390. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 391. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 392. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 393. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 394. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 395. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 396. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 397. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 398. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 399. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 400. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 401. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 402. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 403. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 404. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 405. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 406. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 407. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 408. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 409. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 410. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 412. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 413. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 414. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 415. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 416. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 417. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 420. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 421. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 422. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 423. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 424. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 425. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 426. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 427. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 428. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 429. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 430. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 431. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 432. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 433. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 434. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 435. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 436. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 437. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 438. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 440. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 441. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 442. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 443. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 444. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 445. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 446. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 447. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 448. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 449. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 450. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 451. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 452. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 453. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 454. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 455. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 456. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 457. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 458. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 459. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 461. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 462. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 463. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 464. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 465. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 466. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 467. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 468. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 469. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 470. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 471. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 472. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 473. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 474. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 475. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 476. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 477. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 478. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 480. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 481. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 482. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 483. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 484. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 485. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 486. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 487. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 488. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 489. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 490. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 491. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 492. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 494. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 495. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 496. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 497. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 498. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 499. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 500. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 501. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 502. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 503. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 504. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 505. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 506. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 507. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 508. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 509. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 510. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 511. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 512. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 513. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 514. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 515. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 516. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 517. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 518. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 519. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 520. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 521. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 522. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 523. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 526. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 527. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 528. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 529. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 530. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 531. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 532. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 533. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 534. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 535. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 536. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 537. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 538. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 539. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 540. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 542. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 543. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 544. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 545. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 546. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 547. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 548. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 549. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 550. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 551. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 552. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 553. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 554. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 555. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 556. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 557. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 558. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 559. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 560. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 561. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 562. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 563. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 564. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 565. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 566. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 567. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 568. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 569. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 570. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 571. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 572. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 573. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 574. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 575. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 576. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 577. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 579. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 580. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 581. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 582. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 583. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 584. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 585. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 586. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 587. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 588. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 589. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 590. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 591. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 592. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 593. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 595. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 596. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 597. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 598. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 599. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 600. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 601. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 602. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 603. IBM CORPORATION: KEY FACTS, 2020
TABLE 605. IBM CORPORATION: STRATEGIC DEVELOPMENTS, 2019-2020
TABLE 606. EXSCIENTIA: KEY FACTS, 2020
TABLE 607. EXSCIENTIA: STRATEGIC DEVELOPMENTS, 2019-2020
TABLE 608. GNS HEALTHCARE: KEY FACTS, 2020
TABLE 609. GNS HEALTHCARE: STRATEGIC DEVELOPMENTS, 2019-2020
TABLE 610. DEEPMIND: KEY FACTS, 2020
TABLE 611. DEEPMIND: STRATEGIC DEVELOPMENTS, 2018-2019
TABLE 612. BENEVOLENT AI: KEY FACTS, 2020
TABLE 613. BENEVOLENT AI: STRATEGIC DEVELOPMENTS, 2019-2020
TABLE 614. BIOSYMETRICS: KEY FACTS, 2020
TABLE 615. BIOSYMETRICS: STRATEGIC DEVELOPMENTS, 2020
TABLE 616. EURETOS: KEY FACTS, 2020
TABLE 617. EURETOS: STRATEGIC DEVELOPMENTS, 2018
TABLE 618. BERG LLC: KEY FACTS, 2020
TABLE 619. BERG LLC: STRATEGIC DEVELOPMENTS, 2020
TABLE 621. ATOMWISE, INC.: STRATEGIC DEVELOPMENTS, 2018-2020
TABLE 624. MICROSOFT CORPORATION: KEY FACTS, 2020
TABLE 625. MICROSOFT CORPORATION: REVENUE (US$ MN), 2016-2020
TABLE 626. MICROSOFT CORPORATION: STRATEGIC DEVELOPMENTS, 2018-2020
TABLE 627. NVIDIA CORPORATION: KEY FACTS, 2020
TABLE 628. NVIDIA CORPORATION: REVENUE (US$ MN), 2015-2019
TABLE 629. NVIDIA CORPORATION: STRATEGIC DEVELOPMENTS, 2020
TABLE 630. CYCLICA: KEY FACTS,
TABLE 631. CYCLICA: STRATEGIC DEVELOPMENTS, 2018-2020
TABLE 632. DEEP GENOMICS: KEY FACTS, 2020
TABLE 633. DEEP GENOMICS: STRATEGIC DEVELOPMENTS, 2018-2020
TABLE 634. CLOUD PHARMACEUTICALS, INC.: KEY FACTS, 2020
TABLE 636. OWKIN, INC.: KEY FACTS, 2020
TABLE 637. OWKIN, INC.: STRATEGIC DEVELOPMENTS, 2020
TABLE 638. VERGE GENOMICS: KEY FACTS, 2020
TABLE 639. VERGE GENOMICS: STRATEGIC DEVELOPMENTS, 2018
TABLE 640. XTALPI, INC.: KEY FACTS, 2020
TABLE 641. XTALPI, INC.: STRATEGIC DEVELOPMENTS, 2019
List of Figures
FIGURE 1. GLOBAL AI IN DRUG DISCOVERY MARKET SEGMENTATION
FIGURE 2. MARKET DYNAMICS: GLOBAL AI IN DRUG DISCOVERY MARKET, 2021
FIGURE 3. PORTER’S FIVE FORCES ANALYSIS: GLOBAL AI IN DRUG DISCOVERY MARKET, 2021
FIGURE 4. VALUE CHAIN ANALYSIS: AI IN DRUG DISCOVERY MARKET 101
FIGURE 5. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 6. GLOBAL AI IN DRUG DISCOVERY MARKET BY TECHNOLOGY MARKET SHARE (%), 2021, 2026, AND 2031
FIGURE 7. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 8. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 9. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 10. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 11. GLOBAL MACHINE LEARNING MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 12. GLOBAL MACHINE LEARNING MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 13. GLOBAL MACHINE LEARNING MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 14. GLOBAL MACHINE LEARNING MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 15. GLOBAL MACHINE LEARNING MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 16. GLOBAL OTHER TECHNOLOGIES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 17. GLOBAL OTHER TECHNOLOGIES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 18. GLOBAL OTHER TECHNOLOGIES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 19. GLOBAL OTHER TECHNOLOGIES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 20. GLOBAL OTHER TECHNOLOGIES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 21. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 22. GLOBAL AI IN DRUG DISCOVERY MARKET BY APPLICATION MARKET SHARE (%), 2021, 2026, AND 2031
FIGURE 23. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 24. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 25. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 26. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 27. GLOBAL DRUG OPTIMIZATION & REPURPOSING MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 28. GLOBAL DRUG OPTIMIZATION & REPURPOSING MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 29. GLOBAL DRUG OPTIMIZATION & REPURPOSING MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 30. GLOBAL DRUG OPTIMIZATION & REPURPOSING MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 31. GLOBAL DRUG OPTIMIZATION & REPURPOSING MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 32. GLOBAL PRECLINICAL TESTING MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 33. GLOBAL PRECLINICAL TESTING MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 34. GLOBAL PRECLINICAL TESTING MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 35. GLOBAL PRECLINICAL TESTING MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 36. GLOBAL PRECLINICAL TESTING MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 37. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 38. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 39. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 40. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 41. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 44. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 45. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 46. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 47. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 48. GLOBAL ONCOLOGY MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 49. GLOBAL ONCOLOGY MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 50. GLOBAL ONCOLOGY MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 51. GLOBAL ONCOLOGY MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 52. GLOBAL ONCOLOGY MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 53. GLOBAL NEURODEGENERATIVE DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 54. GLOBAL NEURODEGENERATIVE DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 55. GLOBAL NEURODEGENERATIVE DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 56. GLOBAL NEURODEGENERATIVE DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 57. GLOBAL NEURODEGENERATIVE DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 58. GLOBAL CARDIOVASCULAR DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 59. GLOBAL CARDIOVASCULAR DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 60. GLOBAL CARDIOVASCULAR DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 61. GLOBAL CARDIOVASCULAR DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 63. GLOBAL METABOLIC DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 64. GLOBAL METABOLIC DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 65. GLOBAL METABOLIC DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 66. GLOBAL METABOLIC DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 67. GLOBAL METABOLIC DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 68. GLOBAL INFECTIOUS DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 69. GLOBAL INFECTIOUS DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 70. GLOBAL INFECTIOUS DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 71. GLOBAL INFECTIOUS DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 72. GLOBAL INFECTIOUS DISEASES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 73. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 74. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 75. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 76. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 77. GLOBAL OTHERS MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 78. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), 2020-2031
FIGURE 79. GLOBAL AI IN DRUG DISCOVERY MARKET BY END USER MARKET SHARE (%), 2021, 2026, AND 2031
FIGURE 80. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 81. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 82. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 83. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 84. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 86. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 87. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 88. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 89. GLOBAL CONTRACT RESEARCH ORGANIZATION MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 90. GLOBAL CONTRACT RESEARCH ORGANIZATION MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 91. GLOBAL CONTRACT RESEARCH ORGANIZATION MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 92. GLOBAL CONTRACT RESEARCH ORGANIZATION MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 93. GLOBAL CONTRACT RESEARCH ORGANIZATION MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 94. GLOBAL RESEARCH CENTRE & ACADEMIC AND GOVERNMENT INSTITUTES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 95. GLOBAL RESEARCH CENTRE & ACADEMIC AND GOVERNMENT INSTITUTES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 96. GLOBAL RESEARCH CENTRE & ACADEMIC AND GOVERNMENT INSTITUTES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 97. GLOBAL RESEARCH CENTRE & ACADEMIC AND GOVERNMENT INSTITUTES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 98. GLOBAL RESEARCH CENTRE & ACADEMIC AND GOVERNMENT INSTITUTES MARKET AND FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 99. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY REGION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 100. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY REGION MARKET FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 101. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY REGION MARKET FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 102. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY REGION MARKET FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 103. GLOBAL AI IN DRUG DISCOVERY MARKET AND FORECAST BY REGION MARKET FORECAST: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 104. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 105. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 106. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 107. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 108. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 109. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 110. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 111. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 112. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 113. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 114. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 115. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 116. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 117. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 118. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 119. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 120. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 121. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 122. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 123. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 125. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 126. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 127. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 128. NORTH AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 129. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 130. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 131. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 132. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 133. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 134. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 135. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 136. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 137. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 138. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 139. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 140. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 141. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 142. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 143. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 144. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 145. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 146. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 147. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 148. U.S. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 149. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 150. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 151. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 152. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 153. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 154. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 155. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 156. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 157. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 158. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 159. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 160. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 161. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 162. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 163. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 164. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 165. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 166. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 167. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 168. CANADA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 169. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 170. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 171. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 172. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 173. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 174. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 175. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 176. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 177. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 178. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 179. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 180. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 181. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 182. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 183. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 184. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 185. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 186. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 187. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 188. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 189. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 190. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 191. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 192. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 193. EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 194. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 195. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 196. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 197. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 198. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 199. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 200. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 201. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 202. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 203. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 204. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 205. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 206. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 207. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 208. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 209. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 210. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 211. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 212. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 213. U.K. AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 214. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 215. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 216. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 217. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 218. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 219. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 220. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 221. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 222. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 223. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 224. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 225. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 226. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 227. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 228. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 229. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 230. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 231. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 232. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 233. GERMANY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 234. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 235. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 237. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 238. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 239. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 240. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 241. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 242. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 243. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 244. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 245. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 246. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 247. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 248. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 249. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 250. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 251. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 252. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 253. FRANCE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 254. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 255. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 256. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 257. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 258. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 259. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 260. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 261. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 263. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 264. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 265. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 266. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 267. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 268. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 269. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 270. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 271. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 272. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 273. ITALY AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 274. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 275. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 276. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 277. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 278. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 279. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 280. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 281. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 282. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 283. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 284. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 285. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 286. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 287. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 288. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 289. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 290. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 291. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 292. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 293. SPAIN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 294. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 295. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 296. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 297. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 298. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 299. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 300. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 301. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 302. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 303. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 304. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 305. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 306. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 307. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 308. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 309. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 310. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 311. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 312. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 313. REST OF EUROPE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 314. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 315. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 316. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 317. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 318. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 319. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 320. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 321. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 322. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 323. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 324. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 325. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 326. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 327. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 328. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 329. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 330. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 331. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 332. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 333. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 334. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 335. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 336. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 337. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 338. ASIA PACIFIC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 339. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 340. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 341. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 342. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 343. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 344. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 345. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 346. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 347. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 348. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 349. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 350. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 351. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 352. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 353. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 354. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 355. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 356. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 357. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 358. CHINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 359. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 360. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 361. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 362. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 363. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 364. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 365. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 366. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 367. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 368. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 369. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 370. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 371. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 372. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 373. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 374. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 375. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 376. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 377. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 378. INDIA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 379. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 380. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 381. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 382. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 383. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 384. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 385. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 386. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 387. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 388. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 389. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 390. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 391. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 392. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 393. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 394. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 395. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 396. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 397. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 398. JAPAN AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 399. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 400. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 401. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 402. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 403. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 404. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 405. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 406. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 407. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 408. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 409. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 410. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 411. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 412. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 413. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 414. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 415. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 416. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 417. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 418. SOUTH KOREA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 419. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 420. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 421. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 422. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 423. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 424. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 425. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 426. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 427. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 428. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 429. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 430. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 431. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 432. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 433. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 434. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 435. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 436. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 437. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 438. REST OF APAC AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 439. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 440. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 441. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 442. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 443. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 444. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 445. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 446. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 447. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 448. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 449. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 450. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 451. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 452. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 453. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 454. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 455. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 456. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 457. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 458. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 459. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 460. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 461. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 462. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 463. LATIN AMERICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 464. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 465. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 466. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 467. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 468. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 469. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 470. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 471. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 472. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 473. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 474. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 475. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 476. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 477. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 478. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 479. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 480. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 481. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 482. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 483. BRAZIL AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 484. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 485. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 486. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 487. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 488. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 489. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 490. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 491. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 492. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 493. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 494. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 495. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 496. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 497. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 498. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 499. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 500. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 501. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 502. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 503. MEXICO AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 504. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 505. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 506. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 507. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031
FIGURE 508. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 509. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 510. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 511. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 512. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 513. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 514. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 515. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 516. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 517. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 518. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 519. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 520. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 521. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 522. ARGENTINA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 524. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 525. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 526. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 527. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 528. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 529. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 530. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 531. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 532. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 533. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 534. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 535. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 536. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 537. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 538. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 539. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 540. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 541. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 542. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 543. REST OF LATAM AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 544. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 545. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 546. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 547. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 548. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 549. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 550. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 551. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 552. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 553. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY COUNTRY: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 554. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 555. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 556. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 557. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 558. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 559. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 560. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 561. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 562. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 563. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 564. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 565. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 566. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 567. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 568. MIDDLE EAST & AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY COUNTRY: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 569. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 571. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 572. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 573. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 574. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 575. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 576. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 577. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 578. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 579. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 580. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 581. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 582. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 583. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 584. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 585. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 586. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 587. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 588. SOUTH AFRICA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 589. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 590. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AND AGR (%)2020-2031
FIGURE 591. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 592. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 593. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 594. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 595. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 597. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 598. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 599. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 600. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 601. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 602. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 603. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 604. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 605. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 606. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 607. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 608. UAE AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 609. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 610. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 611. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 612. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031
FIGURE 613. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 614. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 615. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 616. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 617. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 618. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 619. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 620. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 621. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 622. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 623. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 624. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 625. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY TECHNOLOGY: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 626. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY APPLICATION: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 627. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY THERAPEUTIC AREA: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 628. REST OF MEA AI IN DRUG DISCOVERY MARKET AND FORECAST, BY END USER: REVENUES ($ MN), AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 629. GLOBAL MARKET SHARE ANALYSIS (VALUE %), 2020
FIGURE 630. IBM CORPORATION: HISTORICAL REVENUE (US$ MN), 2015-2019
FIGURE 631. MICROSOFT CORPORATION: HISTORICAL REVENUE (US$ MN), 2016-2020
FIGURE 632. NVIDIA CORPORATION: HISTORICAL REVENUE (US$ MN), 2015-2019
FIGURE 634. GLOBAL AI IN DRUG DISCOVERY MARKET SHARE (%), BY APPLICATION, 2021, 2026 AND 2031
FIGURE 635. GLOBAL AI IN DRUG DISCOVERY MARKET SHARE (%), BY THERAPEUTIC AREA, 2021, 2026 AND 2031
FIGURE 636. GLOBAL AI IN DRUG DISCOVERY MARKET SHARE (%), BY END USER, 2021, 2026 AND 2031
FIGURE 637. GLOBAL AI IN DRUG DISCOVERY MARKET SHARE (%), BY REGION, 2021, 2026 AND 2031
Companies Profiled in the Report:
Atomwise, Inc.
Benevolent AI
BERG LLC
BioSymetrics
Cloud Pharmaceuticals
Cyclica
Deep Genomics
DeepMind
Euretos
Exscientia
GNS Healthcare
IBM Corporation
Insitro
Microsoft Corporation
NVIDIA Corporation
Owkin, Inc.
Verge Genomics
XtalPi
List of Companies Mentioned in the Report:
Accenture
AdventHealth
AstraZeneca
ATAI Lifesciences AG
Bayer
BioMarin Pharmaceuticals, Inc.
BioMotiv
Blue Oak Pharmaceuticals
Boehringer Ingelheim
Bridge Biotherapeutics
Bristol Myers Squibb
Celgene
Cereval Therapeutics
Charles River Laboratories
Datavant
Deutsche Telekom
Diamond Light Source
DNDi
Eli Lilly and Company
Elsevier
Enamine, Ltd.
Eurofarma
Excelra
FMC Corporation
Gilead Sciences, Inc.
GitHub, Inc.
GlaxoSmithKline
Google, Inc.
GT Apeiron Therapeutics
Gustave Roussy
Hansoh Pharmaceutical Group Company Limited
Haystack Sciences
HollandBIO
Huadong Medicine
Instana
Janssen
Mannin Research
NeuroTheryX Canada, Ltd.
Novartis
Nuance Communications, Inc.
NYU Langone Health
Pfizer
Rallybio
Red Hat, Inc.
Roche
Sema4
ServiceNow
Sophia Genetics
SRI International
Sumitomo Dainippon Pharma
Temasek
UnitedHealth Group
Wave Life Sciences, Ltd.
WuXi AppTec
Zeiss Group
List of Organisations:
Alliance for Clinical Trials in Oncology
Bill & Melinda Gates Foundation
Brigham and Women's Hospital
Cancer Research UK Imperial Centre
CINECA
Duke University
FedDev Ontario
Genome Institute
Harvard Medical School
Institut Carnot CALYM
Merck Global Health Innovation Fund
Multiple Myeloma Research Foundation
U-M Life Sciences Institute
University of California
University of Michigan College of Pharmacy
University of Pittsburgh
Vanderbilt University Medical Center
World Health Organization
Atomwise, Inc.
Benevolent AI
BERG LLC
BioSymetrics
Cloud Pharmaceuticals
Cyclica
Deep Genomics
DeepMind
Euretos
Exscientia
GNS Healthcare
IBM Corporation
Insitro
Microsoft Corporation
NVIDIA Corporation
Owkin, Inc.
Verge Genomics
XtalPi
List of Companies Mentioned in the Report:
Accenture
AdventHealth
AstraZeneca
ATAI Lifesciences AG
Bayer
BioMarin Pharmaceuticals, Inc.
BioMotiv
Blue Oak Pharmaceuticals
Boehringer Ingelheim
Bridge Biotherapeutics
Bristol Myers Squibb
Celgene
Cereval Therapeutics
Charles River Laboratories
Datavant
Deutsche Telekom
Diamond Light Source
DNDi
Eli Lilly and Company
Elsevier
Enamine, Ltd.
Eurofarma
Excelra
FMC Corporation
Gilead Sciences, Inc.
GitHub, Inc.
GlaxoSmithKline
Google, Inc.
GT Apeiron Therapeutics
Gustave Roussy
Hansoh Pharmaceutical Group Company Limited
Haystack Sciences
HollandBIO
Huadong Medicine
Instana
Janssen
Mannin Research
NeuroTheryX Canada, Ltd.
Novartis
Nuance Communications, Inc.
NYU Langone Health
Pfizer
Rallybio
Red Hat, Inc.
Roche
Sema4
ServiceNow
Sophia Genetics
SRI International
Sumitomo Dainippon Pharma
Temasek
UnitedHealth Group
Wave Life Sciences, Ltd.
WuXi AppTec
Zeiss Group
List of Organisations:
Alliance for Clinical Trials in Oncology
Bill & Melinda Gates Foundation
Brigham and Women's Hospital
Cancer Research UK Imperial Centre
CINECA
Duke University
FedDev Ontario
Genome Institute
Harvard Medical School
Institut Carnot CALYM
Merck Global Health Innovation Fund
Multiple Myeloma Research Foundation
U-M Life Sciences Institute
University of California
University of Michigan College of Pharmacy
University of Pittsburgh
Vanderbilt University Medical Center
World Health Organization
Download sample pages
Complete the form below to download your free sample pages for Artificial Intelligence (AI) in Drug Discovery Market Report 2021-2031Related reports
-
Direct-to-Patient Market Report 2021-2031
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this...Full DetailsPublished: 24 June 2021 -
Nasal Drug Delivery Technology Market Report 2022-2032
The nasal drug delivery market will expand rapidly due to rising patient preference for nasal medication delivery due to ease...Full DetailsPublished: 18 January 2022 -
Drug Discovery Outsourcing Market Report 2020-2030
The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug...
Full DetailsPublished: 24 August 2020 -
Vaccine Adjuvants Market Report 2021-2031
The opportunity for innovation within the vaccine adjuvants market remains strong. As time progresses, the technology used in the manufacturing...Full DetailsPublished: 02 February 2021 -
Cancer Immunotherapy Drug Discovery Outsourcing Market Report 2020-2030
Overall world revenue for Cancer Immunotherapy Drug Discovery Outsourcing will surpass $750 million in 2020, our work calculates. We predict...
Full DetailsPublished: 01 January 1970 -
Antiviral Drugs Treatment Market Report 2021-2031
Rising incidences of viral infection; increasing geriatric population is projected to propel the demand for anti-viral drugs; advancement in anti-viral...Full DetailsPublished: 26 April 2021 -
Stem Cell Technologies and Applications Market Report 2021-2031
Factors such as rising prevalence of chronic and genetic diseases, increasing application areas of stem cell technologies, technological advancements, and...Full DetailsPublished: 10 August 2021 -
European Antibiotics Market Report 2021-2031
Penicillin segment holds majority of the market share owing to maximum prescription as well as the most generic manufacturers throughout...Full DetailsPublished: 31 March 2021 -
Protein Engineering Market Report 2021-2031
Growing investment in drug R&D by pharmaceutical and biopharmaceutical companies; investment by government for novel vaccine development for COVID-19; rising...Full DetailsPublished: 11 February 2021 -
Anti-Infective Agents Market Report 2021-2031
Rising incidences of infectious diseases is one of the prime factors driving the growth of the global anti-infective agents market...Full DetailsPublished: 11 May 2021
Download sample pages
Complete the form below to download your free sample pages for Artificial Intelligence (AI) in Drug Discovery Market Report 2021-2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: jamie.roberts@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Jamie Roberts stating your chosen report title to jamie.roberts@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email jamie.roberts@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034
The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.
18 April 2024
Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034
The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.
17 April 2024
Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034
The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.
12 April 2024
Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034
The global Inflammatory Bowel Diseases (IBD) Drugs market was valued at US$27.53 billion in 2023 and is projected to grow at a CAGR of 6.2% during the forecast period 2024-2034.
11 April 2024
